Oral Cancer

Is this drugs for woman only ## This is a combined hormonal tablet, which contains Estrogen and Progestin and yes, they are most commonly used in females, because these hormones are present in the female body in much higher amounts. Learn more: Though the Progestin is sometimes used in men to treat prostate cancer. Is there anything else I can help with?

1 REPLY

## I am a nursing student. My final exam is focused on palliative care. I would appreciate any information about prescribing in palliative care. The scenario for my exam states that the patient is to be commenced on Morphine Sulphate oral solution, as Oromorph 10mg/5ml, 5mg four hourly to titrate his analgesic requirements. (The patient is suffering from terminal prostate cancer). Any information will be greatly welcomed. Thanks!!

1 REPLY

How fast should amox K Clav 875/125mg take to heal an oral infection? I need to rule out tonsil cancer. If the antibiotic does not work it is more likely to be cancer. ## Or it could just be an antibiotic resistant bacteria, so you'd need to try a different stronger one to treat it, or it could be recurrent tonsillitis, which may require removal of the tonsils. I had many tonsil infections over the years and the possibility of cancer was never mentioned to me, but I did end up finally having to have them out when I was 20. Learn more Augmentin details here. As to the antibiotic, there shouldn't be any worsening after 24 hours, if it's working and then you should start to see improvement within about 3 days. What other antibiotics have you tried? Have they done throat cultures?

1 REPLY

Dx: prostate cancer getting CT of abd/pelvis, need to take omnipaque as oral prep what side effects should I expect ## Hi Hardy, The most frequently reported adverse reactions with Omnipaque are headache, mild to moderate pain including backache, neckache and stiffness, nausea, and vomiting. These reactions usually occur 1 to 10 hours after injection, and almost all occur within 24 hours. They are usually mild to moderate in degree, lasting for a few hours, and usually disappearing within 24 hours. Rarely, headaches may be severe or persist for days. Headache is often accompanied by nausea and vomiting and tends to be more frequent and persistent in patients not optimally hydrated. Does this help answer your question? Please post back if you have any other comments or concerns regarding...

2 REPLIES

hydrocodone bitartrate elixir is being discontinued, i can only take oral solutions, ; oral cancer surgery, is there a substitution> ## Hi jetta, From what I could gather, the following three pain medications are also listed as having an oral liquid solution available: methadone oxycodone dilaudid (hydromorphone) There probably are many more options out there, but those are just a few possible alternatives I came across after a quick google search. I would also recommend discussing other options with your doctor, since he/she knows your medical history and can make certain suggestions based on what's worked for you in the past. I hope this helps! ## thank you david, they have replaced my lortab elixir with the hydrocodone 7.5/3.25 instead of 7.5/500-- i did not know they had an ...

4 REPLIES

what side affects does tamazapine have? and what is it given for. My friend has oral cancer and has been given this drug. ## I think you mean the drug Temazepam - this is typically prescribed as a short-term treatment of severe or debilitating sleeplessness. For more information about this drug, including possible side effects, please see the following page: Do you have any other questions or information to add? Please post back if you do...

1 REPLY

Talazoparib Tosylate

Talazoparib, sold under the brand name Talzenna, is an orally available poly ADP ribose polymerase (PARP) inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations.[2] Talazoparib is similar to the first in class PARP inhibitor, olaparib.[3][4] It was approved in October 2018, in the United States and June 2019, in the European Union for germline BRCA-mutated, HER2-negative locally advanced or metasta...

Drug Index

Talazoparib, sold under the brand name Talzenna, is an orally available poly ADP ribose polymerase (PARP) inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations.[2] Talazoparib is similar to the first in class PARP inhibitor, olaparib.[3][4] It was approved in October 2018, in the United States and June 2019, in the European Union for germline BRCA-mutated, HER2-negative locally advanced or metasta...

Rubitecan

Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by SuperGen (now Astex Pharmaceuticals, Inc.; a member of the Otsuka Group). Contents 1 History 2 Synthesis 3 Use as Anti-Cancer Drug 4 References History On January 27, 2004, SuperGen announced that it has completed the submission of an NDA for rubitecan to the US FDA,[2] and was accepted for filing on March 2004.[3] In January 2005, and under the direction of then-C...

Drug Index

Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by SuperGen (now Astex Pharmaceuticals, Inc.; a member of the Otsuka Group). Contents 1 History 2 Synthesis 3 Use as Anti-Cancer Drug 4 References History On January 27, 2004, SuperGen announced that it has completed the submission of an NDA for rubitecan to the US FDA,[2] and was accepted for filing on March 2004.[3] In January 2005, and under the direction of then-C...

Nintedanib

Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.[3] In March 2020, it was approved for use in the United States to treat chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait).[4] It is the first treatment for this group of fibrosing lung diseases that wo...

Imatinib, STI-571

Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral chemotherapy medication used to treat cancer.[2] Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodys...

Imatinib, STI-571

Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral chemotherapy medication used to treat cancer.[2] Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodys...

Lapatinib

Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast cancer and other solid tumours.[1] It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways.[2] It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer ...

Drug Index

Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.[3] In March 2020, it was approved for use in the United States to treat chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait).[4] It is the first treatment for this group of fibrosing lung diseases that wo...

Alectinib

Alectinib (INN,[2] marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK)[3][4] and is used to treat non-small-cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. Contents 1 History, clinical trials, Approvals and medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacok...

Drug Index

Alectinib (INN,[2] marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK)[3][4] and is used to treat non-small-cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. Contents 1 History, clinical trials, Approvals and medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacok...

Drug Index

Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast cancer and other solid tumours.[1] It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways.[2] It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer ...

Drug Index

Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral chemotherapy medication used to treat cancer.[2] Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodys...

Lorlatinib

Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.[1] Contents 1 Medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 Chemistry 7 History 7.1 Clinical studies 7.2 Approval...